Interestingly, blocking the interaction of PD-L1/PD1 using the human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody, durvalumab plus gemcitabine and cisplatin as first-line therapy, demonstrated a shorter overall survival trend in the ERBB2 altered CCA subtype. Here, ERBB2 is linked to cholangiocarcinoma.